News

University of California associate professor of Neurological Surgery and principal investigator of the study Dr Nicholas Butowski is sponsoring and conducting the Phase I trial and it is

SPK-RPE65 targets a group of blinding conditions known as inherited retinal dystrophies (IRDs). IRDs are caused by autosomal recessive mutations in the RPE65 gene, for which currently there

Complying with OECD GLP, ISO, US FDA GLP regulatory guidelines, Vanta offers toxicology evaluation services for the pharmaceutical, biotech, food supplements and feed additives industries. The acquisition allows

NK1 receptor antagonists are administered in combination with a 5-HT3 receptor antagonist for the prevention of CINV. Heron Therapeutics’ lead investigational product candidate, SUSTOL® (granisetron injection, extended release),

The FDA is expected to review the submission and comment on the proposed study population, clinical endpoints, and statistical analyses within 30 to 45 days. The submission of

These methods further strengthen ViaCyte’s intellectual property platform, providing alternative ways to produce pancreatic progenitor and endocrine cells that have potential for use in cell replacement therapies. Pancreatic

Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme, a Sanofi company. Cerdelga was approved by the U.S. Food and Drug

The deal, funded through a combination of cash, debt and equity, includes the purchase of Omega’s equity for €2.48bn and the assumption of €1.1bn in debt. The acquisition

Currently, the company is evaluating the efficacy and safety of SD-809 to treat chorea associated with this disorder in a Phase III registration clinical trial and is scheduled